Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT06056791 is registered in ClinicalTrials.gov with Inmune Bio, Inc. as lead sponsor.

NCT NCT06056791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06056791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Inmune Bio, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2023
Completion date
September 10, 2025
Enrollment
12 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, mcrpc, metastatic castration-resistant prostate cancer